The Interplay Between the Oncogene and Ribosomal Proteins in Osteosarcoma Onset and Progression: Potential Mechanisms and Indication of Candidate Therapeutic Targets

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39596100

Authors

Ania Naila Guerrieri

Claudia Maria Hattinger

Federica Marchesini

Martina Melloni

Massimo Serra

Toni Ibrahim

Marianna Penzo

Affiliations

Soon will be listed here.

Abstract

High-grade osteosarcoma (OS) is the most common primary bone tumor mainly affecting children and young adults. First-line treatment consists of neo-adjuvant chemotherapy with doxorubicin, cisplatin, and methotrexate and surgery. The mean long-term survival rate for localized disease at diagnosis is 65-70%, dropping down to 20% when metastases are present at diagnosis. Therefore, curing OS is a clinical challenge, particularly for patients that do not respond to standard treatments. has frequently been reported to be involved in the pathogenesis of OS and its high expression may be associated with drug resistance and patients' worse prognosis. Moreover, is a master regulator of ribosomal proteins (RPs) synthesis and ribosome biogenesis (RiBi), which is often up-regulated in human tumors. In recent years, RPs have been recognized not only for their traditional role in ribosome assembly but also for their extra-ribosomal functions, many of which are linked to the onset and progression of cancer. In this review we focus on the role and possible interplay of and RPs expression in association with drug resistance and worse prognosis in OS and discuss therapeutic options that target de-regulated , RiBi, or RPs, which are already clinically available or under evaluation in clinical trials.

References

Shen D, Liang X, Suzuki T, Gottesman M . Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol. 2006; 69(4):1383-8. PMC: 1409811. DOI: 10.1124/mol.105.017525. View

Poortinga G, Wall M, Sanij E, Siwicki K, Ellul J, Brown D . c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res. 2010; 39(8):3267-81. PMC: 3082905. DOI: 10.1093/nar/gkq1205. View

Mosey R, Floreancig P . Isolation, biological activity, synthesis, and medicinal chemistry of the pederin/mycalamide family of natural products. Nat Prod Rep. 2012; 29(9):980-95. DOI: 10.1039/c2np20052j. View

Han S, Siegel D, Morrison K, Hergenrother P, Movassaghi M . Synthesis and anticancer activity of all known (-)-agelastatin alkaloids. J Org Chem. 2013; 78(23):11970-84. PMC: 3920459. DOI: 10.1021/jo4020112. View

Gomez-Roman N, Grandori C, Eisenman R, White R . Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003; 421(6920):290-4. DOI: 10.1038/nature01327. View

Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S . Role of GLI2 in the growth of human osteosarcoma. J Pathol. 2011; 224(2):169-79. DOI: 10.1002/path.2880. View

Chi X, Ji T, Li J, Xu J, Tang X, Xie L . Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma. Cancer Manag Res. 2021; 13:5101-5111. PMC: 8254031. DOI: 10.2147/CMAR.S317809. View

Amati B, Dalton S, Brooks M, Littlewood T, Evan G, Land H . Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992; 359(6394):423-6. DOI: 10.1038/359423a0. View

Haddach M, Schwaebe M, Michaux J, Nagasawa J, OBrien S, Whitten J . Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Med Chem Lett. 2014; 3(7):602-6. PMC: 4025669. DOI: 10.1021/ml300110s. View

10.

Zang Y, Ran X, Yuan J, Wu H, Wang Y, Li H . Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer. Brief Bioinform. 2024; 25(2). PMC: 10859687. DOI: 10.1093/bib/bbae023. View

11.

Zheng S, Yao Y, Dong Y, Lin F, Zhao H, Shen Z . Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol. 2009; 135(8):1025-31. DOI: 10.1007/s00432-008-0538-4. View

12.

Shi S, Luo H, Wang L, Li H, Liang Y, Xia J . Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma. Biomed Pharmacother. 2020; 133:110906. DOI: 10.1016/j.biopha.2020.110906. View

13.

Doan Thi Thuy A, Trinh Thi Thanh V, Doan Thi Mai H, Le H, Litaudon M, Nguyen V . Cytotoxic Alkaloids from Leaves of Pilea aff. martinii. Planta Med. 2019; 85(6):496-502. DOI: 10.1055/a-0826-0483. View

14.

Lai C, Pan S, Yang X, Chang L, Chang Y, Yang P . Depletion of 4E-BP1 and regulation of autophagy lead to YXM110-induced anticancer effects. Carcinogenesis. 2013; 34(9):2050-60. DOI: 10.1093/carcin/bgt146. View

15.

Chen D, Zhao Z, Huang Z, Chen D, Zhu X, Wang Y . Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018; 6:11. PMC: 5884797. DOI: 10.1038/s41413-018-0009-8. View

16.

Edwards-Hicks J, Su H, Mangolini M, Yoneten K, Wills J, Rodriguez-Blanco G . MYC sensitises cells to apoptosis by driving energetic demand. Nat Commun. 2022; 13(1):4674. PMC: 9363429. DOI: 10.1038/s41467-022-32368-z. View

17.

Tsoi H, You C, Leung M, Man E, Khoo U . Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. Cancers (Basel). 2022; 14(5). PMC: 8909264. DOI: 10.3390/cancers14051251. View

18.

Masso-Valles D, Soucek L . Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020; 9(4). PMC: 7226798. DOI: 10.3390/cells9040883. View

19.

Pellegrino S, Terrosu S, Yusupova G, Yusupov M . Inhibition of the Eukaryotic 80S Ribosome as a Potential Anticancer Therapy: A Structural Perspective. Cancers (Basel). 2021; 13(17). PMC: 8430933. DOI: 10.3390/cancers13174392. View

20.

van Riggelen J, Yetil A, Felsher D . MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010; 10(4):301-9. DOI: 10.1038/nrc2819. View